Nyra is developing a transcatheter technology (CARLEN), which modifies the native mitral valve leaflets with a proprietary implant, to correct for deficiencies that otherwise lead to mitral regurgitation, while preserving the physiological valve geometry.
Market
Cardiovascular
Location
Decatur,
GA,
USA
Coinvestors
Broadview Ventures, Epidarex Capital, Georgia Research Alliance, Vensana Capital